Did You Know...
...that Thomas Edison's patent application on his phonograph was approved by the Patent Office in just seven weeks? In contrast, it took Gordon Gould, the inventor of the laser, 30 years to obtain his patent -- finally awarded in 1988!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7462592 | Compositions and methods for polynucleotide delivery This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency o... | 12/09/2008 |
| 7459599 | Methods for producing proteins using silkworm middle silk gland-specific gene expression system Transgenic silkworms comprising GFP whose expression is regulated by the sericin gene promoter were produced. Observation of the silk glands of the last instar larvae of the silkworms showed fluorescence only in the middle silk glands. GFP was secreted from middle s... | 12/02/2008 |
| 7459540 | Fibroblast growth factor-like polypeptides The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for ar... | 12/02/2008 |
| 7446185 | Her2/neu target antigen and use of same to stimulate an immune response A recombinant polynucleotide encoding a Her2/neu target antigen is provided, as is a recombinant Her2/neu target antigen polypeptide. Also provided are methods of using such a recombinant polynucleotide to express a Her2/neu target antigen in a cell. In addition, me... | 11/04/2008 |
| 7442783 | Natural IgM antibodies and inhibitors thereof The invention provides natural IgM antibody inhibitors that may be used to treat various inflammatory diseases or disorders. ... | 10/28/2008 |
| 7442768 | Fluorescent protein and gene encoding the same The present invention provides a novel fluorescent protein the wavelength of the maximum of the fluorescence of which exists in a wavelength side longer than 510 nm, and which exhibits yellow fluorescence or yellowish green fluorescence and can be expressed in a het... | 10/28/2008 |
| 7435871 | Transgenic animals bearing human Igλ light chain genes The invention relates to transgenic animals bearing one or more human λ light chain loci. The invention also relates to methods and compositions for making transgenic animals that have incorporated human λ light chain loci. The invention further relates to methods... | 10/14/2008 |
| 7427495 | Methods of using Bcl-2 for the therapeutic treatment and prevention of diseases The invention provides a method of treating a disease or pathological condition resulting in apoptotic cell death. The method includes increasing the activity of Bcl-2 in cells affected by the disease or pathological condition. Diseases or pathological conditions ca... | 09/23/2008 |
| 7422736 | Somatic pluripotent cells The present invention discloses a cultured somatic animal cell having a normal karyotype; the cell develops into an embryoid body when induced in vitro, or develops into a teratoma when introduced into a SCID mouse. Also disclosed is a method of producing such a cel... | 09/09/2008 |
| 7423194 | Animal models for demyelination disorders This invention is in the field of neurology. Specifically, the invention relates to the discovery and characterization of molecular components that play a role in neuronal demyelination or remyelination. In addition, the invention relates to the generation of an ani... | 09/09/2008 |
| 7413853 | Modulation of metabolism of steroids and xenobiotics In accordance with the present invention, there are provided methods for modulating Phase II conjugating enzymes such as, for example, UGTs. Phase II conjugating enzymes such as UGTs function in concert with Phase I monooxygenase enzymes such as cytochrome P450 enzy... | 08/19/2008 |
| 7408047 | Fibroblast growth factor-like polypeptides The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for ar... | 08/05/2008 |
| 7405287 | Method of treating a cancer The present invention provides isolated nucleic acids encoding delta DNA methyltransferase 3B molecules that are involved in the treatment and prevention of cancers such as, but not limited to, lung cancer. The delta DNA methyltransferase 3B molecules of the present... | 07/29/2008 |
| 7396904 | Tumor-associated peptides binding to MHC-molecules The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibil... | 07/08/2008 |
| 7396680 | Stem cell-specific promoters and their use The present invention relates to a method of isolating stem cells from a mixed population of different cell types. This method involves selecting a promoter which functions only in said stem cells and not in the other cell types. The promoter can have a nucleotide s... | 07/08/2008 |
| 7393525 | Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same A method for introducing and expressing genes in animal cells is disclosed comprising infecting said the animal cells with live invasive bacteria, wherein bacteria contain a eukaryotic expression cassette encoding said gene. The gene may encode, e.g., a vaccine anti... | 07/01/2008 |
| 7388087 | Enhancement of immune response to vaccine by interferon alpha Exogenous cDNA capable of expressing interferon α activity, exogenous interferon α protein, inducers of endogenous interferon α protein activity, inducers of endogenous interferon β protein activity, inducers of endogenous interfereon Γ activity, or inducers of... | 06/17/2008 |
| 7384784 | Pax-encoding vector and use thereof The present invention provides cells transformed with a nucleotide sequence encoding Pax7, Pax3 or both. The present invention also pertains to Pax-encoding vector that comprises a sequence encoding Pax7, Pax3 or an active variant or fragment thereof, which can be u... | 06/10/2008 |
| 7381711 | Substances for preventing and treating autoimmune diseases A substance for preventing, delaying the onset of, or treating one or more than one autoimmune disease, the substance comprising a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one ... | 06/03/2008 |
| 7378569 | Transgenic pigs carrying both hHO-1 and hDAF transgenes for xenotransplantation The invention provides a transgenic animal carrying two transgenes, one encoding a human decay accelerating factor (hDAF) and the other encoding a human heme oxygenase-1 (hHO)-1, which are useful for providing cells, tissues or organs therefrom for xenotransplantati... | 05/27/2008 |
| 7378276 | Method of inducing memory B cell development and terminal differentiation A method is disclosed herein for inducing differentiation of a B cell progenitor into a memory B cells and/or a plasma cell. The method includes contacting a population of cells including a mature B cell or a B cell progenitor with an effective amount of IL-21, and ... | 05/27/2008 |
| 7375092 | Lunasin peptides The invention provides methods and compositions of selectively disrupting mitotic function in a target cell demonstrating undesirable mitotic function. Suitable target cells include mammalian, plant and bacterial cells, which cells may be in vitro or in situ. The ge... | 05/20/2008 |
| 7374937 | Isolation and expansion of human marrow stromal cells The invention includes in vitro methods of inducing and enhancing proliferation of human marrow stromal cells for use in, for example, gene therapy and transplantation methods. The invention also includes a method of assessing the expandability (i.e., proliferative ... | 05/20/2008 |
| 7371920 | Transgenic mouse model of neurodegenerative disorders The present invention provides a transgenic animal model of Alzheimer's Disease designated TgCRND8 as well as a method for making such model, which allows for the characterization of the etiology of the disease as well as for provide a system for the development and... | 05/13/2008 |
| 7371539 | Targeted polypeptide degradation This invention pertains to compositions, methods, cells and organisms useful for selectively localizing polypeptides to the proteasome for degradation. Therapeutic methods and pharmaceutical compositions for treating disorders associated with the expression and/or a... | 05/13/2008 |
| 7368532 | Constructs for delivery of therapeutic agents to neuronal cells A non-toxic polypeptide, for delivery of a therapeutic agent to a neuronal cell, comprises a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the translocation domain i... | 05/06/2008 |
| 7368546 | Human SAA3 nucleic acid molecule, protein, and methods of use for same A nucleotide sequence encoding human serum amyloid A3 (SAA3), isolated, purified and characterized from human mammary epithelial cells is disclosed. Proteins encoded thereby and methods of use for the same are also disclosed. ... | 05/06/2008 |
| 7364900 | Multi-lineage directed induction of bone marrow stromal cell differentiation Methods of inducing differentiation of mammalian bone marrow stromal cells into cells of multiple embryonic lineages by contacting marrow stromal cells with precursor differentiation-inducing compounds followed by contacting the partially differentiated precursor ce... | 04/29/2008 |
| 7354759 | DNA vaccines expressing hypervariable VH-CDR3 idiotypic determinants The present invention relates to a method for inducing the immune response of an individual against B-lymphoproliferative disorders. The method is based on DNA vaccination with the short peptide encompassing the CDR3 hypervariable region of immunoglobulin heavy chai... | 04/08/2008 |
| 7351875 | FcγRIIa transgenic animal model for autoimmune disease The present invention provides a FcγRIIa transgenic non-human animal model for autoimmune disease, particularly arthritis. This invention also provides a method of using this model to screen compounds that can reduce aberrant immune activity including aberrant immu... | 04/01/2008 |
| 7342146 | Neurodegenerative non-human transgenic mammal expressing TrkA fusion protein The present invention provides a neurodegenerative, non-human transgenic mammal whose cells contain a TrkA-hFc transgene for encoding at least a TrkA fusion protein and the use thereof. ... | 03/11/2008 |
| 7332645 | IL-21 as a regulator of immunoglobin production A transgenic mouse is disclosed herein whose somatic and germ cells comprise a disrupted IL-21 receptor gene, the disruption being sufficient to inhibit the binding of IL-21 to an IL-21 receptor, and a disrupted IL-4 gene, the disruption being sufficient to inhibit ... | 02/19/2008 |
| 7332644 | Non-human animal model of oligodendrocyte developmental disorder The objects of the present invention is to provide a preventive method for the progress of neuropsychiatric disorders, a therapeutic agent for neuropsychiatric disorders, a screening method thereof, and a therapeutic method through the analysis of the mechanisms lea... | 02/19/2008 |
| 7326692 | Induction of immunity using inhibitors of granzymes The present invention provides methods for enhancing host immunity to a virus and/or a cancer and methods for enhancing the cytotoxic T-cell (CTL) mediated immune responses by providing granzyme B inhibitors to a subject. One objective of the invention is to induce ... | 02/05/2008 |
| 7320787 | Redirection of cellular immunity by protein tyrosine kinase chimeras Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerou... | 01/22/2008 |
| 7316812 | Cells expressing anti-Fc receptor binding components Cells transformed to express on their surface a component which binds to an Fc receptor of an effector cell are disclosed. Also disclosed are expression vectors used to transform the cells. Once transformed, the cells bind to effector cells via the Fc receptor of th... | 01/08/2008 |
| 7301068 | Nonhuman model animal of Th2-mediated hyperimmune response An object of the present invention is to provide a nonhuman model animal of Th2-mediated hyperimmune response lacking PIR-B gene function on its chromosome by which the Th2-mediated immune response mechanism and allergy onset mechanism in vivo can be analyzed and wh... | 11/27/2007 |
| 7300657 | Recombinant viral-based malaria vaccines The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium ... | 11/27/2007 |
| 7300651 | Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1 The present invention provides methods of delaying development of CEA-associated tumors using the anti-idiotype antibody 3H1, particularly in high-risk individuals. ... | 11/27/2007 |
| 7291604 | Methods of treating restenosis Restenosis in a subject can be treated by administering to a tissue, e.g., a blood vessel, of the subject an agent that increases SERCA activity. For example, a stent that is coated with the agent can be introduced into a blood vessel. ... | 11/06/2007 |
